Reuters logo
J&J unit ends hepatitis C drug development in crowded market
September 11, 2017 / 7:00 AM / 11 days ago

J&J unit ends hepatitis C drug development in crowded market

(Reuters) - Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

Janssen said it would not continue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals.

The ongoing phase II studies with JNJ-4178 will be completed as planned, with no additional development thereafter, Janssen said in a statement on Monday.

Janssen’s hepatitis research and development efforts will continue to focus on chronic hepatitis B, the unit said.

Janssen co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus, a few years ago. In collaboration with Medivir AB , Janssen later launched the second-generation protease inhibitor OLYSIO, which is approved in several countries.

Reporting by Kanishka Singh in Bengaluru; Editing by Gopakumar Warrier

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below